The South Bend Clinic

South Bend, Indiana 46617

1 studies enrolling now · 22 studies all time

What they study most

Acne Vulgaris, Atopic Dermatitis, Colorectal Cancer, Genital Psoriasis, Moderate Psoriasis, Plaque Psoriasis, Primary Immunodeficiency, Psoriasis, Psoriasis (PsO), Seasonal Allergic Rhinitis, Severe Psoriasis, T2DM

Studies at this site

• Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus — Recruiting now
• CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin — Running, not enrolling
• Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis — Completed
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Running, not enrolling
• Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: "Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C" — Completed
• Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C" — Completed
• Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis — Completed
• A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis — Completed
• Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis — Completed
• A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis — Stopped early
• A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) — Completed
• A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis — Completed
• A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis — Completed
• Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency — Completed
• A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis — Completed
• Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects — Completed
• BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris — Completed
• Trial of STAHIST in Seasonal Allergic Rhinitis — Completed
• A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis — Completed